AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24456698 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC (Brief Motivational Counseling)
Number of subjects: 150
Study 24456698 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC+Phone (BMC plus monthly phone calls by a Community Health Worker)
Number of subjects: 150
Study 24456698 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC+Home (BMC plus monthly home visits by a Community Health Worker)
Number of subjects: 150
Study 21803976 — intervention group
Group type: EXPERIMENTAL
Intervention: NaClO(3) 60 mg·kg of BW(‐1)
Number of subjects: 76
Study 21803976 — intervention group
Group type: EXPERIMENTAL
Intervention: NaClO(3) 90 mg·kg of BW(‐1)
Number of subjects: 76
Study 21803976 — intervention group
Group type: EXPERIMENTAL
Intervention: NaClO(3) 150 mg·kg of BW(‐1)
Number of subjects: 76
Study 21803976 — intervention group
Group type: EXPERIMENTAL
Intervention: NaClO(3) 300 mg·kg of BW(‐1)
Number of subjects: 76
Study 21803976 — intervention group
Group type: EXPERIMENTAL
Intervention: NaClO(3) 450 mg·kg of BW(‐1)
Number of subjects: 76
Study 21803976 — intervention group
Group type: COMPARATOR
Intervention: Control (saline NaCl, 30 mg·kg of BW(‐1) for lambs; 150 mg·kg of BW(‐1) for ewes)
Number of subjects: 76
Study 19486475 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 10
Study 19486475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 10
Study 19486475 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching (control)
Number of subjects: 10
Study 19398935 — intervention group
Group type: EXPERIMENTAL
Intervention: (32)P‐chromic phosphate colloids (32)P‐CP) injection during surgery
Number of subjects: 73
Study 19398935 — intervention group
Group type: COMPARATOR
Intervention: Control group (tumor resections only)
Number of subjects: 73
Study 19398935 — intervention group
Group type: EXPERIMENTAL
Intervention: (32)P‐CP injection
Number of subjects: 73
Study 16416607 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to one surgical wound
Number of subjects: 20
Study 16416607 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied to the second surgical wound (Control)
Number of subjects: 20
Study 12584537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 186
Study 12584537 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 186
Study 10593714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) formulations of rifampicin, isoniazid and pyrazinamide
Number of subjects: 20
Study 10593714 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations of rifampicin, isoniazid and pyrazinamide
Number of subjects: 20
Study 8709658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention letters sent to physicians for 174 patients
Number of subjects: 335
Study 8709658 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention letters)
Number of subjects: 335
Study 1750473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ampicillin‐sulbactam and indomethacin
Number of subjects: 86
Study 1750473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7066144 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 5 micrograms kg‐1
Number of subjects: 80
Study 7066144 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 7.5 micrograms kg‐1
Number of subjects: 80
Study 7066144 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 10 micrograms kg‐1
Number of subjects: 80
Study 7066144 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 15 micrograms kg‐1
Number of subjects: 80
Study 30445989 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education regarding edible oils for four consecutive weeks (Group A)
Number of subjects: 800
Study 30445989 — intervention group
Group type: COMPARATOR
Intervention: Blank control (Group B)
Number of subjects: 800
Study 26993737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (writing about personally relevant values)
Number of subjects: 0
Study 26993737 — intervention group
Group type: COMPARATOR
Intervention: Control task (writing about values relevant to another person)
Number of subjects: 0
Study 26993737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 0
Study 23900406 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological working memory tasks
Number of subjects: 35
Study 23900406 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial working memory tasks
Number of subjects: 35
Study 23900406 — intervention group
Group type: COMPARATOR
Intervention: Control conditions with minimal working memory demands
Number of subjects: 35
Study 23900406 — intervention group
Group type: EXPERIMENTAL
Intervention: Central executive and phonological storage/rehearsal subsystems
Number of subjects: 35
Study 22318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation study group (not specified in detail)
Number of subjects: 195
Study 22318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 1 stress
Number of subjects: 195
Study 22318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 26 sleep
Number of subjects: 195
Study 22318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and younger age
Number of subjects: 195
Study 22318635 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 1 anxiety, depression, and stress; week 26 sleeping; rehabilitation study group
Number of subjects: 195
Study 22318635 — intervention group
Group type: COMPARATOR
Intervention: Study group
Number of subjects: 195
Study 20089221 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, 600 mg every 12 h intravenously
Number of subjects: 81
Study 20089221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 20089221 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 81
Study 17822820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 161
Study 15641045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 200
Study 15641045 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 200
Study 15228256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 29
Study 15228256 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 29
Study 11933280 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntleigh Nimbus 3 in conjunction with the Aura cushion (Group A)
Number of subjects: 141
Study 11933280 — intervention group
Group type: COMPARATOR
Intervention: Pegasus Cairwave Therapy System in conjunction with the Proactive 2 Seating cushion (Group B)
Number of subjects: 141
Study 11933280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 8895286 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-dose PCA (VDPCA) - 0.5, 1.0, and 1.5 mg boluses of morphine
Number of subjects: 60
Study 8895286 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose PCA (FDPCA) - 1.0 mg of morphine
Number of subjects: 60
Study 2070384 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish treatments 3 times a week, once a year
Number of subjects: 160
Study 2070384 — intervention group
Group type: COMPARATOR
Intervention: Duraphat varnish treatments every 6 months
Number of subjects: 160
Study 6364775 — intervention group
Group type: EXPERIMENTAL
Intervention: High amylose rice (23 to 25% amylose)
Number of subjects: 33
Study 6364775 — intervention group
Group type: COMPARATOR
Intervention: 0% amylose rice
Number of subjects: 33
Study 31128770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum uromodulin (sUMOD) levels (mean sUMOD level was 127±64ng/mL)
Number of subjects: 933
Study 31128770 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum uromodulin (sUMOD) levels
Number of subjects: 933
Study 31261494 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen 30 or 50 mg/kg
Number of subjects: 12
Study 31261494 — intervention group
Group type: EXPERIMENTAL
Intervention: Eteplirsen treatment
Number of subjects: 12
Study 31261494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28100282 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strength group (SS, SMX/TMP of 400/80 mg daily)
Number of subjects: 183
Study 28100282 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength group (HS, SMX/TMP of 200/40 mg daily)
Number of subjects: 183
Study 28100282 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalation group (ES, started with 40/8 mg daily, increasing to 200/40 mg daily)
Number of subjects: 183
Study 26470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (1600 mg) and vitamin D3 (1000 IU) ingested prior to cycling for 5 months
Number of subjects: 17
Study 26470637 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 17
Study 23224330 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 508
Study 21242642 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM) in combination with Losartan (LOS)
Number of subjects: 0
Study 21242642 — intervention group
Group type: COMPARATOR
Intervention: Losartan (LOS)
Number of subjects: 0
Study 18428069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-Kang-Ning (TKN) capsule
Number of subjects: 64
Study 18428069 — intervention group
Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 64
Study 16611950 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg daily for 10 days)
Number of subjects: 278
Study 16611950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 16611950 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 278
Study 12962869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 0
Study 12962869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) with mycophenolate mofetil (MMF) and steroids
Number of subjects: 0
Study 10849040 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5-HTP), 300 mg per day
Number of subjects: 78
Study 10849040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 9322355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (10 mg/m2 i.v. day 1), Vinblastine (5 mg/m2 i.v. day 1 and 15), Amifostine (910 mg/m2 in short i.v. infusion prior to MMC)
Number of subjects: 6
Study 8401500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested PCR strategy for sex determination at the single cell level by simultaneous amplification of ZFX and ZFY genes
Number of subjects: 194
Study 3536563 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (ABM) taken orally
Number of subjects: 490
Study 3536563 — intervention group
Group type: COMPARATOR
Intervention: Conventional means (control group)
Number of subjects: 490
Study 31074164 — intervention group
Group type: COMPARATOR
Intervention: Traditional supervisor-led clinical session (Group A)
Number of subjects: 71
Study 31074164 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube videos of high educational quality (Group B)
Number of subjects: 71
Study 31074164 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected YouTube videos (Group C)
Number of subjects: 71
Study 29198060 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA administration
Number of subjects: 124
Study 26238598 — intervention group
Group type: EXPERIMENTAL
Intervention: Heinrichs-Carpenter Quality of Life Scale (QLS) total score
Number of subjects: 0
Study 26238598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions of Severity (CGI-S)
Number of subjects: 0
Study 26238598 — intervention group
Group type: EXPERIMENTAL
Intervention: QLS improvers (QLS total score increased ≥ six points)
Number of subjects: 0
Study 26238598 — intervention group
Group type: EXPERIMENTAL
Intervention: QLS domains: 'Interpersonal relations' and 'Intrapsychic foundations'
Number of subjects: 0
Study 1446958 — intervention group
Group type: EXPERIMENTAL
Intervention: Indolidan (IN) administered i.v. at 1,180 +/- 340 micrograms (15 micrograms/kg) over two hours
Number of subjects: 12
Study 1446958 — intervention group
Group type: EXPERIMENTAL
Intervention: Indolidan (IN) administered p.o. at 231 +/- 44 micrograms
Number of subjects: 12
Study 1446958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1446958 — intervention group
Group type: EXPERIMENTAL
Intervention: Indolidan (IN)
Number of subjects: 12
Study 22846396 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg dose of H1N1 vaccine
Number of subjects: 0
Study 22846396 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with licensed trivalent seasonal influenza vaccine
Number of subjects: 0
Study 22846396 — intervention group
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine
Number of subjects: 0
Study 19937106 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention (physical activity guidelines, local municipal healthy active living guide + planning material)
Number of subjects: 85
Study 19937106 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (received physical activity guidelines and a local municipal healthy active living guide)
Number of subjects: 85
Study 18708731 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 + PSK
Number of subjects: 20
Study 18708731 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 20
Study 15781521 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing circuit leak test with non-zero basal flow (BF) of oxygen
Number of subjects: 25
Study 15781521 — intervention group
Group type: COMPARATOR
Intervention: Breathing circuit leak test without non-zero basal flow (BF) of oxygen
Number of subjects: 25
Study 12914507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.3%) eardrops, 5 drops twice daily for 9 days
Number of subjects: 147
Study 12914507 — intervention group
Group type: COMPARATOR
Intervention: Framycetin (0.5%), gramicidin, dexamethasone (FGD) eardrops, 5 drops twice daily for 9 days
Number of subjects: 147
Study 10503681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (800 microg) and nebulized salbutamol (0.15 mg/kg)
Number of subjects: 80
Study 10503681 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg) and nebulized salbutamol (0.15 mg/kg)
Number of subjects: 80
Study 8759565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 78
Study 8759565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg
Number of subjects: 78
Study 8759565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 78
Study 8759565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 1922207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical doxorubicin
Number of subjects: 262
Study 1922207 — intervention group
Group type: COMPARATOR
Intervention: Bacille Calmette-Guérin (BCG)
Number of subjects: 262
Study 7191832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrated amino acid‐carbohydrate solution (PE 900 with 25 g x 1(‐1) amino acids and 50 g x 1(‐1) Polyols)
Number of subjects: 0
Study 7191832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrated amino acid‐carbohydrate solution (PE 900)
Number of subjects: 0
Study 31678833 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis (12.5% THC)
Number of subjects: 91
Study 31678833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low THC cannabis (12.5% THC)
Number of subjects: 91
Study 31678833 — intervention group
Group type: EXPERIMENTAL
Intervention: High THC cannabis (12.5% THC)
Number of subjects: 91
Study 31678833 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis (0.009% THC)
Number of subjects: 91
Study 31678833 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 91
Study 28196279 — intervention group
Group type: EXPERIMENTAL
Intervention: Head lift exercise (HLE), performed 5 days a week for 4 weeks (total of 20 sessions).
Number of subjects: 27
Study 28196279 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same conventional dysphagia therapy without HLE.
Number of subjects: 27
Study 26490493 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (aMeDi score of 6-9)
Number of subjects: 2525
Study 26490493 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (aMeDi score) among subjects carrying the CFH Y402H nonrisk (T) allele
Number of subjects: 2525
Study 26490493 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (aMeDi score) among subjects homozygous for the risk (C) allele
Number of subjects: 2525
Study 24041858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosal halotherapy
Number of subjects: 45
Study 24041858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18209608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate serial casting (same day)
Number of subjects: 12
Study 18209608 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed serial casting (4 weeks later)
Number of subjects: 12
Study 15482056 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic cat meows
Number of subjects: 0
Study 15482056 — intervention group
Group type: COMPARATOR
Intervention: Wild cat vocalizations
Number of subjects: 0
Study 11131342 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin intramuscularly for 4-7 days
Number of subjects: 154
Study 11131342 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime intravenously for 4-7 days
Number of subjects: 154
Study 9291414 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium cromoglycate
Number of subjects: 14
Study 9291414 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 14
Study 8318683 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 244
Study 8318683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 2872794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase therapy (500 National Formulary units/kg intravenously every 6 hours for 48 hours)
Number of subjects: 851
Study 2872794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase therapy
Number of subjects: 851
Study 31437669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative microbiome analysis using 16S-23S rDNA Next Generation Sequencing (NGS)
Number of subjects: 10
Study 31437669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nasal and perineal cultures
Number of subjects: 10
Study 31437669 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis of groin biopsies
Number of subjects: 10
Study 31437669 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without SSI)
Number of subjects: 10
Study 29793800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure sports compression tights (CT)
Number of subjects: 33
Study 29793800 — intervention group
Group type: COMPARATOR
Intervention: Track pants (CON)
Number of subjects: 33
Study 26730183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Number of subjects: 0
Study 26730183 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg
Number of subjects: 0
Study 26730183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 0
Study 26730183 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO)
Number of subjects: 0
Study 26730183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FF/VI and TIO
Number of subjects: 0
Study 24552307 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource priming
Number of subjects: 0
Study 24552307 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive resource priming
Number of subjects: 0
Study 24552307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence priming
Number of subjects: 0
Study 24552307 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 22152634 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual K‐files (group M)
Number of subjects: 45
Study 22152634 — intervention group
Group type: EXPERIMENTAL
Intervention: PathFile rotary instruments (group PF)
Number of subjects: 45
Study 22152634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary instruments (group MT)
Number of subjects: 45
Study 20660140 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental meningococcal serogroup B vaccine (five formulations, n = 25 in each group)
Number of subjects: 150
Study 20660140 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental meningococcal serogroup B vaccine
Number of subjects: 150
Study 20660140 — intervention group
Group type: COMPARATOR
Intervention: Control (VA‐Mengoc‐BC, n = 25)
Number of subjects: 150
Study 17372241 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived ambiguity about mammography recommendations
Number of subjects: 0
Study 16326882 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 50
Study 16326882 — intervention group
Group type: COMPARATOR
Intervention: Standard immobilisation in a cast
Number of subjects: 50
Study 12196053 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg/d
Number of subjects: 36
Study 12196053 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine maleate 12 mg twice daily
Number of subjects: 36
Study 12196053 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 12196053 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine and chlorpheniramine maleate
Number of subjects: 36
Study 9527356 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpick impregnated in 4% NaF
Number of subjects: 24
Study 9527356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.32% NaF
Number of subjects: 24
Study 9527356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse solution containing 0.025% NaF
Number of subjects: 24